Citigroup Inc Relay Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 414,977 shares of RLAY stock, worth $2.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

414,977

Previous 146,263 183.72%

Holding current value

$2.69 Million

Previous $1.61 Million 113.91%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$7.5 - $12.07 $2.02 Million - $3.24 Million	268,714 Added 183.72%	414,977 $3.44 Million
Q4 2023 Feb 09, 2024	SELL	$6.01 - $11.48 $149,174 - $284,945	-24,821 Reduced 14.51%	146,263 $1.61 Million
Q3 2023 Nov 09, 2023	SELL	$8.24 - $12.97 $252,325 - $397,167	-30,622 Reduced 15.18%	171,084 $1.44 Million
Q2 2023 Aug 10, 2023	SELL	$9.99 - $18.27 $1.54 Million - $2.82 Million	-154,406 Reduced 43.36%	201,706 $2.53 Million
Q1 2023 May 11, 2023	BUY	$15.0 - $22.76 $2.2 Million - $3.34 Million	146,872 Added 70.19%	356,112 $5.87 Million

Q4 2022 Feb 09, 2023	BUY	$14.16 - $24.02 $388,861 - $659,637	27,462 Added 15.11%	209,240 $3.13 Million
Q3 2022 Nov 10, 2022	SELL	$18.07 - $31.37 $79,146 - $137,400	-4,380 Reduced 2.35%	181,778 $4.07 Million
Q2 2022 Aug 10, 2022	BUY	$13.31 - $34.88 $2.06 Million - $5.4 Million	154,898 Added 495.52%	186,158 $3.12 Million
Q1 2022 May 12, 2022	SELL	$20.26 - $32.36 $2.6 Million - $4.15 Million	-128,355 Reduced 80.42%	31,260 $936,000
Q4 2021 Feb 10, 2022	BUY	$26.0 - $37.03 $659,932 - $939,895	25,382 Added 18.91%	159,615 $4.9 Million
Q3 2021 Nov 10, 2021	BUY	$29.75 - $37.99 $3.99 Million - $5.1 Million	134,233 New	134,233 $4.23 Million

Others Institutions Holding RLAY

# of Institutions

187

Shares Held

127M

Call Options Held

4.2K

Put Options Held

1.7K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $779M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account